aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.
https://www.news-medical.net/news/20261109/Five-AI-models-tackled-227-pharmacy-exam-questions-Heres-where-they-struggled.aspx
Five leading AI models faced the same 227 infectious disease exam questions, testing whether their accuracy could withstand the demands of specialized knowledge, complex clinical problems, and visual interpretation.
In a recent study published in the journal Scientific Reports, researchers at the University of the Pacific School of Pharmacy, Stockton, USA, compared the accuracy of five large language models (LLMs) in answering infectious disease-related pharmacy examination questions across different pharmacy subject areas, cognitive levels, and question formats.
https://www.statnews.com/2026/11/10/ai-health-advice-accuracy-messaging-risk-behavioral-benchmarking
By Jessica Fishman and John L. Jackson Jr.Nov. 10, 2026
Fishman is a behavioral scientist and faculty director of the Message Effects Lab at the Perelman School of Medicine, University of Pennsylvania. Jackson is an anthropologist and provost at the University of Pennsylvania. He launched the Message Effects Lab while serving as dean of Penn’s Annenberg School for Communication.
Episode 23, AI Series: AI is speeding up the search for new medicines. Can it make the discoveries themselves?
Few people are better placed to answer than Dr. Elias Zerhouni. He ran the National Institutes of Health, then global R&D at Sanofi. He co-founded ModeX Therapeutics, which uses machine learning to design antibodies that don’t exist in nature, and he is now vice chairman and president of its parent company, OPKO Health.
His test for AI: give it every piece of data available in the early 1950s, and it would not have found the double helix. The spark, he argues, is still human.
Chip and Dr. Zerhouni dig into what AI is actually doing in drug development, how the FDA stacks up against regulators abroad, and what a slowdown in AI — and the erosion of American research — could mean for the next generation of cures.
https://www.kff.org/other-health/the-drug-enterprise-in-the-age-of-ai/
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
www.revistamedicos.com.ar //
www.quorumtuc.com.ar //
www.sectorsalud.com.ar //
www.maimonides.edu //
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.documentalistas.org.ar //
www.cpcesfe2.org.ar //
www.nogracias.eu //
www.estenssorome.com.ar //
www.cuautitlan.unam.mx/descargas/licenciaturas/bqd/plandestudio_bqd_ //
www.latamjpharm.org/trabajos/25/2/LAJOP_25_2_6_1_M4M6Z9746D.pdf //
www.nogracias.eu/v_juventud/informacion/informacionver.asp?cod= //
www.colfarse.com.ar //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||